Rock Springs Capital Management LP Prelude Therapeutics Inc Transaction History

Rock Springs Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$11.89 - $31.74 $78,474 - $209,484	6,600 Added 1.82%	368,959 $4.59 Million
Q3 2021 Nov 15, 2021	SELL	$25.78 - $38.65 $515,600 - $773,000	-20,000 Reduced 5.23%	362,359 $11.3 Million
Q2 2021 Aug 16, 2021	BUY	$28.63 - $44.3 $119,215 - $184,465	4,164 Added 1.1%	382,359 $10.9 Million
Q1 2021 May 17, 2021	BUY	$39.27 - $91.68 $700,262 - $1.63 Million	17,832 Added 4.95%	378,195 $16.4 Million
Q4 2020 Feb 16, 2021	BUY	$28.81 - $88.94 $2,881 - $8,894	100 Added 0.03%	360,363 $25.8 Million
Q3 2020 Nov 16, 2020	BUY	$26.2 - $30.13 $9.44 Million - $10.9 Million	360,263 New	360,263 $10.9 Million

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $35.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.